Skip to content

Regeneron & Genentech (almost) settle their VEGF trap dispute

Regeneron Pharmaceuticals Inc (REGN, Tarrytown, New York) has announced a non-exclusive license and partial settlement with Genentech (RHHBY.PK, a unit of the Roche group) related to US sales of the recently launched Eylea product (aflibercept). However, the companies remain in dispute over a number of the same patents in relation to Regeneron’s “Zaltrap”, a formulation of aflibercept currently in Phase III trials for colorectal and prostrate cancer.